Market research
VNRX VolitionRx Limited
AMEX USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 13.622
- Dividend yield
- Not available
- Beta
- 1.17
Profile
Instrument facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 13.622
- Dividend yield
- Not available
- Beta
- 1.17
About
About VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Research context
VolitionRx Limited appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VNRX discussion.
5 years, 6 months ago
VolitionRx Limited is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 851.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12741.3.
VolitionRx Limited's total revenue rose by inf% to $7K since the same quarter in the previous year.
Its net income has dropped by 44.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 413.9% to $9M since the same quarter in the previous year.
Based on the above factors, VolitionRx Limited gets an overall score of 2/5.